Deciphera To Present At American Chemical Society Annual Meeting

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments targeting the tumor cell and the tumor microenvironment, today announced that Daniel Flynn, Ph.D., Deciphera’s Chief Scientific Officer and Founder will give a plenary talk at the upcoming 251st National Meeting & Exposition of the American Chemical Society (ACS), taking place March 13-17, 2016 in San Diego.